Establishing a Model to Identify Mutant Subpopulations That Cause Resistance to Molecularly-Targeted Cancer Therapies.

被引：0
|
作者：
Banda, M. [1 ]
Mckim, K. L. [1 ]
Parsons, B. L. [1 ]
机构：
[1] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
来源：
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
EG-49
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 12 条
  • [1] Establishing a Primary Lung Cancer Model to Identify Mutant Subpopulations That Cause Resistance to Molecularly-targeted Cancer Therapies.
    Banda, M.
    McKim, K. L.
    Myers, M. B.
    Parsons, B. L.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2018, 59 : 49 - 49
  • [2] MOLECULARLY-TARGETED THERAPIES IN THYROID CANCER
    Droz, J.
    De La Fouchardiere, C.
    Bournaud, C.
    Borson-Chazot, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 31 - 31
  • [3] Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
    de Freitas, Antonio Carlos
    Gomes Leitao, Maria da Conceicao
    Coimbra, Eliane Campos
    CURRENT DRUG TARGETS, 2015, 16 (01) : 77 - 91
  • [4] Molecularly-targeted therapies for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2667 - 2679
  • [5] Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies
    Nicos, Marcin
    Wojas-Krawczyk, Kamila
    Krawczyk, Pawel
    Milanowski, Janusz
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 24 (04): : 715 - 723
  • [6] A comprehensive analysis of proteins involved in innate and acquired resistance to molecularly-targeted drugs in breast cancer cells
    Montazeri, Hamid
    CANCER RESEARCH, 2016, 76
  • [7] Use of flow cytometry to identify breast cancer patients likely to benefit from specific targeted therapies.
    Visram, H.
    Sangrar, W.
    George, R.
    Greer, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S174 - S174
  • [8] Genomic profiling to overcome resistance to molecularly targeted therapies in metastatic colorectal cancer
    Strickler, John H.
    CANCER SCIENCE, 2023, 114 : 1522 - 1522
  • [9] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
    Martinez-Hernandez, Maria F.
    Lara-Mejia, Luis
    Izquierdo-Tolosa, Carlos
    Cabrera-Miranda, Luis
    Arrieta, Oscar
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12)
  • [10] TWIST1 is a key mediator of HGF-MET-driven resistance to targeted therapies in EGFR mutant and MET-driven lung cancer
    Yochum, Zachary A.
    Chatterjee, Suman
    Huang, Eric H.
    Maurer, Deena M.
    Attar, Myriam A.
    Dacic, Sanja
    Stabile, Laura P.
    Burns, Timothy F.
    CANCER RESEARCH, 2018, 78 (13)
12